Cerecor (United States)

Preclinical evaluation of the kappa-opioid receptor antagonist CERC-501 as a candidate therapeutic for alcohol use disorders

Esi Domi, Estelle Barbier, Eric Augier et al. · Neuropsychopharmacology · 2018 · 73 citations · Full text

Substance Abuse, Substance Use, Psychiatry +15

Levels of the TNF-Related Cytokine LIGHT Increase in Hospitalized COVID-19 Patients with Cytokine Release Syndrome and ARDS

David S. Perlin, Inbal Zafir‐Lavie, Lori Roadcap et al. · mSphere · 2020 · 40 citations · Full text

Pharmacokinetics and Pharmacodynamics of the Glutamate Carboxypeptidase II Inhibitor 2-MPPA Show Prolonged Alleviation of Neuropathic Pain through an Indirect Mechanism

James J. Vornov, Krystyna M. Wozniak, Ying Wu et al. · Journal of Pharmacology and Experimental Therapeutics · 2013 · 28 citations · Full text

A randomized, double‐blind, placebo‐controlled study of the kappa opioid receptor antagonist, CERC‐501, in a human laboratory model of smoking behavior

Jermaine D. Jones, Shanna Babalonis, Ronald N. Marcus et al. · Addiction Biology · 2019 · 23 citations · Full text

Tobacco Cessation, Substance Use, Nicotine Withdrawal +22

Application of LIBS Technique for the Compositional Analysis of an Attic Black Pottery

Evangelia Xenogiannopoulou, C. Andreouli, C.J. Stournaras · Journal of nano research · 2009 · 22 citations

Compositional Analysis, Libs Technique, Engineering +16